Date published: 2026-5-17

1-800-457-3801

SCBT Portrait Logo
Seach Input

U11 Inhibitors

U11 inhibitors are a class of chemical compounds that interact with the U11 component of the minor spliceosome, a less well-known counterpart to the major spliceosome involved in the splicing of a subset of pre-messenger RNA (pre-mRNA) molecules. The minor spliceosome, which includes the U11 snRNP, is responsible for the recognition and excision of minor class introns. These introns are less common than the major class introns typically targeted by the major spliceosome. U11 inhibitors are designed to selectively bind to the U11 snRNP or associated factors, thereby disrupting its normal function. Through this binding, such inhibitors can affect the splicing process of pre-mRNAs that are substrates for the minor spliceosome. The chemical nature of U11 inhibitors can vary widely, ranging from small organic molecules to larger biopolymers, all sharing the commonality of their target specificity.

The exploration and refinement of U11 inhibitors involves a sophisticated understanding of the biochemistry and structure of the minor spliceosome. The U11 snRNP is a complex entity, composed of numerous proteins and a specific U11 small nuclear RNA (snRNA), which together form a structure capable of recognizing and binding to the minor class splice sites on pre-mRNA. Inhibitors must be designed to interact with this complex in a way that does not affect the major spliceosome, requiring a high degree of selectivity. The design process generally starts with the identification of potential binding sites, which could be on the U11 snRNA itself or on one of the associated proteins. Advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, or cryo-electron microscopy may be used to elucidate the three-dimensional structure of the U11 snRNP, providing insights that guide the chemical synthesis of potential inhibitors. Subsequent in vitro and in vivo studies aim to characterize the binding efficiency, specificity, and the exact mechanism by which these compounds interfere with the U11 snRNP's role in the splicing process.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Pladienolide B

445493-23-2sc-391691
sc-391691B
sc-391691A
sc-391691C
sc-391691D
sc-391691E
0.5 mg
10 mg
20 mg
50 mg
100 mg
5 mg
$299.00
$5699.00
$11099.00
$25500.00
$66300.00
$2875.00
63
(2)

Disrupts the spliceosome complex, which can indirectly affect proteins involved in RNA splicing, including U11.

LGK 974

1243244-14-5sc-489380
sc-489380A
5 mg
50 mg
$359.00
$1295.00
2
(0)

Alters splicing factor 3B complex, potentially changing splicing patterns that U11 may influence.

Spliceostatin A

391611-36-2sc-507481
1 mg
$1800.00
(0)

Binds to the splicing factor SF3b and can alter splicing processes involving U11.

Isoginkgetin

548-19-6sc-507430
5 mg
$225.00
(0)

A dual splicing inhibitor that can modulate splicing events and affect proteins such as U11's interaction with RNA.

Tunicamycin

11089-65-9sc-3506A
sc-3506
5 mg
10 mg
$172.00
$305.00
66
(3)

Inhibits RNA synthesis and may indirectly alter the functional landscape in which U11 operates.

Thiolutin

87-11-6sc-200387
sc-200387A
1 mg
5 mg
$101.00
$406.00
1
(2)

A general inhibitor of transcription that could indirectly decrease the levels of RNA available for U11 binding.